Stolt-Nielsen Limited Reports Unaudited Results For the Second Quarter and First Half of 2021
LONDON, July 1, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the second quarter and first half of 2021. The Company reported a second-quarter net profit attributable to shareholders of $7.8 million, with revenue of $526.9 million, compared with a net profit attributable to shareholders of $2.5 million, with revenue of $480.2 million, in the first quarter of 2021. The net profit attributable to shareholders for the first six months was $10.3 million, with revenue of $1,007.1 million, compared with a net loss attributable to shareholders of $16.3 million, with revenue of $1,000.5 million, in the first half of 2020.
Highlights for the second quarter, compared with the first quarter, were:
- Stolt Tankers reported operating profit of $12.6 million, marginally down from $12.9 million.
- The Stolt Tankers Joint Service (STJS) Sailed-in Time-Charter Index fell slightly to 0.51 from 0.52.
- Stolthaven Terminals reported operating profit of $18.3 million, up from $15.7 million driven by $2.7 million higher revenue and the reversal of a first-quarter tax charge at a JV terminal with a favourable quarter-on-quarter impact of $1.8 million.
- Stolt Tank Containers reported operating profit of $12.5 million, up from $8.0 million, reflecting strong volumes and improved margins.
- Stolt Sea Farm reported an operating loss before fair value adjustment of biomass of
$1.4 million compared with an operating loss of $0.4 million.
- Corporate and Other reported an operating loss of $0.9 million compared with a loss of $2.2 million. The improvement was mainly due to a reduction in profit sharing accruals.
Niels G. Stolt-Nielsen, Chief Executive Officer of Stolt-Nielsen Limited, commented: “During the second quarter we saw an increase in activity across the board, although this is not fully reflected in the financial results. At Stolt Tankers we saw an increase in overall volume following the delivery of the CTG ships. However, a reduction in contract volumes resulting from the Houston freeze in February and reduced acid nominations, required us to fill capacity with lower-paying spot business while bunker prices continued to rise, which resulted in a slightly lower time-charter equivalent. At Stolt Tank Containers the improvement in earnings was due to a continued strong increase in shipments. At Stolthaven Terminals we saw an increase in utilisation and throughput volumes, but pockets of weakness in Asia Pacific and Australia held the overall results down. At Stolt Sea Farm we are seeing strong demand for our species in all markets due to the end of the wild-catch season. Further price increases are expected during the traditionally strong summer season.
“With the delivery of the five CTG ships and the 2,600 newly leased tank containers, and the commissioning of additional storage capacity, the three logistics businesses are well positioned to capitalise on the pending recovery. I remain positive about the market outlook for Stolt Tankers, where we have seen a recovery in COA volumes. At Stolthaven Terminals utilisation has continued to improve steadily over recent months, with an expectation that rates will follow. Stolt Tank Containers continue to set new shipment records on a monthly basis driven by strong demand across a number of regions. At Stolt Sea Farm, the new Cervo and Tocha farms are both performing beyond our expectations. Biomass growth is stronger than we first anticipated, and we expect harvesting to begin at Tocha as early as August, four months ahead of schedule. This additional volume is welcome as we have seen a rapid rise in prices subsequent to quarter-end, which is set to continue through the peak summer season.
“In an effort to accelerate the roll-out of vaccines, Stolt Tankers has begun its own vaccination programme for crew members. During the quarter approximately 350 crew were vaccinated, with a further 800 targeted during the third quarter.”
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Ahold Delhaize share buyback update27.7.2021 08:00:00 CEST | Press release
Zaandam, the Netherlands, July 27, 2021 – Ahold Delhaize has repurchased 253,889 of Ahold Delhaize common shares in the period from July 19, 2021 up to and including July 23, 2021. The shares were repurchased at an average price of € 25.49 per share for a total consideration of € 6.5 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 22,071,395 common shares for a total consideration of € 512.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2021/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company27.7.2021 07:01:34 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021. Business highlights Daridorexant for the treatment of insomnia under review with US FDA, EMA, and SwissmedicNine scientific presentations for daridorexant shared at SLEEP 2021Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimodClazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021“SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021Results for MODIFY Phase 3 study with lucerastat for Fabry
Hyloris to Report 2021 Half-Year Results on 4 August 202127.7.2021 07:00:00 CEST | Press release
Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast: Belgium +32 2 79 338 47 France +33 1 70 700 781 Netherlands + 31 20 795 6614 United Kingdom +44 2071 928 338 United States +1 646 741 3167 Confirmation code 2687826 Following the call, a replay of the webcast will be available on the events page of the Hyloris website. About Hyloris Phar
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor27.7.2021 07:00:00 CEST | Press release
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatme
Wereldhave N.V.: Results H1 202127.7.2021 07:00:00 CEST | Press release
Key items Major step in phasing out France: sold four out of six French assets for € 305mBenelux disposal program finalized, Koningshoek sold above book value LTV down to 46% - pro-forma for four asset French disposal 42%Dutch valuations stabilizing for the first time in nine valuation roundsAs a result of disposals, outlook 2021 direct result now at € 1.75 - 1.85 per shareOutlook direct result 2022 reiterated at € 1.40 - € 1.50 per share; to be followed by 4 - 6% annual growthDividend guidance 2021 minimum € 1.00 per share Attachment Wereldhave pr 2021-H1 - vFINAL
Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000
PRESS RELEASE: BIGBEN: Q1 2021/22 Sales26.7.2021 17:50:00 CEST | Press release
Bigben Press release Lesquin, 26 July 2021 18:00 hrs Q1 2021/22 Sales: 56.7 M€ (+2.8%) High sales historyforNacon Gaming Favourable base effect for Audio-Telco Confirmation of FY 2021/22 and FY 2022/23 targets IFRS – M€ Sales 2021/2022 2020/2021 Change 1st Quarter Nacon Gaming Bigben Audio-Telco 56.7 33.7 23.0 55.2 38.0 17.2 +2.8% -11.3% +33.9% Non audited data In Q1 FY 2021/22 (April 1 to June 30, 2021), Bigben posted sales of €56.7 million, an increase of 2.8%, driven by Audio-Telco, which benefited from a favourable comparison basis, unlike the Nacon Gaming business unit, demonstrating the benefit from being present across several markets. NACON GAMING In Q1 2021/22, Nacon achieved sales of 33.7 M€, down 11.3% on Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. Games: The segment posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, whose back catalogue sales had been boosted by 340% by lockdown. The back catalogue demons